Literature DB >> 11272267

Proteinase 3, Wegener's autoantigen: from gene to antigen.

Y M van der Geld1, P C Limburg, C G Kallenberg.   

Abstract

Proteinase 3 (PR3) is one of four serine protease homologues in the azurophilic granules of neutrophils and granules of monocytes. It is of importance that anti-neutrophil cytoplasmic antibodies (ANCA) in patients with Wegener's granulomatosis (WG) are mainly directed against PR3 only. Furthermore, PR3 is overexpressed in a variety of acute and chronic myeloid leukemia cells. Cytotoxic T lymphocytes specific for a PR3-derived peptide have been shown to specifically lyse leukemia cells that overexpress PR3. This review will focus on PR3 and the characteristics of PR3 that might implicate this particular antigen in the pathogenesis of WG and as target for immunotherapy in myeloid leukemias. We will discuss the genetic localization and gene regulation of PR3, the processing, storage, and expression of the PR3 protein, and the physiological functions of PR3, and compare this with the three other neutrophil-derived serine proteases: human leukocyte elastase, cathepsin G, and azurocidin. Three main differences are described between PR3 and the other serine proteases. This makes PR3 a very intriguing protein with a large array of physiological functions, some of which may play a role in ANCA-associated vasculitidis and myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11272267

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  25 in total

1.  Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects.

Authors:  Achille Aouba; Christian Pagnoux; Boris Bienvenu; Alfred Mahr; Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2007-09-12       Impact factor: 8.667

2.  Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Authors:  Tian-Hui Yang; Lisa S St John; Haven R Garber; Celine Kerros; Kathryn E Ruisaard; Karen Clise-Dwyer; Gheath Alatrash; Qing Ma; Jeffrey J Molldrem
Journal:  J Immunol       Date:  2018-07-18       Impact factor: 5.422

Review 3.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

4.  Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener's autoantigen.

Authors:  Francisco Silva; Amber M Hummel; Dieter E Jenne; Ulrich Specks
Journal:  J Autoimmun       Date:  2010-12       Impact factor: 7.094

5.  Proteinase 3-dependent caspase-3 cleavage modulates neutrophil death and inflammation.

Authors:  Fabien Loison; Haiyan Zhu; Kutay Karatepe; Anongnard Kasorn; Peng Liu; Keqiang Ye; Jiaxi Zhou; Shannan Cao; Haiyan Gong; Dieter E Jenne; Eileen Remold-O'Donnell; Yuanfu Xu; Hongbo R Luo
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

6.  Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3.

Authors:  L Armstrong; S I H Godinho; K M Uppington; H A Whittington; A B Millar
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

Review 7.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 8.  ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients.

Authors:  Divi Cornec; Emilie Cornec-Le Gall; Fernando C Fervenza; Ulrich Specks
Journal:  Nat Rev Rheumatol       Date:  2016-07-28       Impact factor: 20.543

9.  Inactivation of human neutrophil elastase by 1,2,5-thiadiazolidin-3-one 1,1 dioxide-based sulfonamides.

Authors:  Yi Li; Qingliang Yang; Dengfeng Dou; Kevin R Alliston; William C Groutas
Journal:  Bioorg Med Chem       Date:  2007-10-18       Impact factor: 3.641

Review 10.  Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?

Authors:  C Beauvillain; Y Delneste; G Renier; P Jeannin; J F Subra; A Chevailler
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.